ReviewActa diabetologica2026
Targeting ceramides in metabolic syndrome: recent advances and therapeutic opportunities.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ceramides are bifunctional molecules that act as both structural constituents of cellular membranes and bioactive effectors in sphingolipid signaling. Their metabolic perturbation is a hallmark of metabolic syndrome, such as obesity, insulin resistance, type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and atherosclerosis. Among the numerous ceramide species, the long-chain species C16:0 and C18:0 have garnered particular attention due to their robust pathogenic roles and strong associations with human disease. This review critically examines the potential of ceramides as predictive biomarkers and provides novel translational perspectives for the clinical management of metabolic syndrome.
Indexed as
Identifiers
42862333What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.